ArticleAmerican journal of hematology2023

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.

Amer M Zeidan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.